ClinicalTrials.gg
WithdrawnNCT04420130Updated Oct 4, 2022

A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis(SHR-1210-HLJ-009)

An interventional study of Camrelizumab and Chemotherapy in Pancreatic Cancer and Liver Metastasis, sponsored by Yanqiao Zhang. Withdrawn. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-10-04.

Sponsored by Yanqiao Zhang · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
Failed to pass ethics committee review

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is a a single-arm, prospective study of Camrelizumab combined with ablation and chemotherapy for patients with Pancreatic cancer liver metastasis.

The main purpose of this study is to evaluate the safety and tolerability of Camrelizumab combined with ablation and chemotherapy as a treatment of Pancreatic cancer liver metastasis.

02

Conditions studied

  • Pancreatic Cancer
  • Liver Metastasis
03

In context

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Lead sponsor

Yanqiao Zhang is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with liver of pancreatic cancer diagnosed by histology or cytology;
  • Must have CT or MRI examination in the last 3 months;
  • With measurable tumor lesions (spiral CT scan ≥10mm, meet 1.1 standard);
  • Expected survival time> 3 months;
  • The interval between the end of the patient's previous chemotherapy or chemotherapy must be more than 6 months;
  • No radiation therapy (unless there is at least one measurable target lesion in the non-irradiated area);
  • Must score pain;
  • Age: 18 to 70 years old, male or female;
  • PS: 0-1 points;
  • The functions of important organs meet the following requirements:

    1. ≥1.5×109/L, ≥100×109/L, ≥9g/dL;
    2. ≤ 1.5 times (patients drained by retrograde technique may be included); and AST ≤ 5 times ULN;
    3. Creatinine \<120 μmol/L, or rate> 60 mL/min;
  • Women of childbearing age must undergo a negative pregnancy test (βHCG) before starting treatment. Women and men of childbearing age (sexual relationships with women of childbearing age) must agree to use them effectively during treatment and 6 months after the last dose of treatment measures;
  • Signature of patient information and .

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or nursing, or have fertility but refuse to take measures;
  • During the enrollment period, a serious active infection requiring antibiotic intravenous treatment occurred;
  • Those who are allergic to test drugs;
  • Presence of ≥2 grade neuropathy ( 5.0);
  • Uncontrolled, symptomatic or those with a history of difficult-to-control mental illness or severe intellectual or cognitive dysfunction;
  • Suffering from active, known or suspected diseases (including but not limited to: uveitis, enteritis, hepatitis, pituitary inflammation, nephritis, vasculitis, hyperthyroidism, hypothyroidism and the need for bronchodilators Treatment of asthma, etc.). Subjects with hypothyroidism who only need hormone replacement therapy and skin diseases that do not require systemic treatment (such as vitiligo, psoriasis, or hair loss) can be selected;
  • Have been vaccinated or will be vaccinated with within 30 days before the administration of Camrelizumab;
  • Congestive heart failure, uncontrolled arrhythmia, myocardial infarction, unstable angina, stroke or within 6 months; or other patients who cannot tolerate surgery;
  • Suffering from other malignant tumors within 5 years, except for fully treated cervical carcinoma in situ or squamous cell carcinoma of the skin, or basal cell carcinoma of the skin that has been basically controlled;
  • Patients who cannot comply with the trial protocol or cannot cooperate with follow-up;
  • The patient has already participated in another clinical trial;
  • People deprived of their liberty or guardianship;
  • Unable to receive medical supervision during the trial due to geographical, social or psychological reasons;
  • Patients who cannot follow the trial protocol or cannot cooperate with follow-up;
  • The researchers believe that it is not appropriate to participate in this experiment.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Camrelizumab combined with ablation and chemotherapy

    First, patients with liver metastases from pancreatic cancer are given ablation of liver metastases, and conventional chemotherapy plus camrelizumab is performed 1 week after surgery. If patients have multiple metastases, ablation treatment needs to be performed in stages, each ablation After 1 week of treatment, sequential chemotherapy + camrelizumab were reinfused, and the efficacy was evaluated every 2 cycles until the disease progressed or the patient could not tolerate it.

    Drug: Camrelizumab · Drug: Chemotherapy · Procedure: Ablation

Interventions

  • Camrelizumab was administered 200mg iv every 3 weeks

  • DrugChemotherapy

    The chemotherapy regimen may be a standard regimen for routine treatment of advanced pancreatic cancer.

  • ProcedureAblation

    First give pancreatic cancer patients with liver metastases to ablation of liver metastases

06

What researchers measure

Primary outcomes

  1. 6-month PFS rate

    6-month progression-free survival rate

    Time frame: From date of starting treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months.

Secondary outcomes

  1. ORR

    Overall Response Rate

    Time frame: From the first drug administration up to two years

  2. DCR

    Disease Control Rate

    Time frame: From the first drug administration up to two years

  3. PFS

    Progression Free Survival

    Time frame: From the first drug administration up to two years

  4. Incidence of Treatment-Emergent Adverse Events

    adverse events/serious adverse events

    Time frame: from the first drug administration to within 90 days for the last Camrelizumab combined with ablation and chemotherapy

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2020; primary completion for Aug 2022, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2020
First posted
Jun 9, 2020
StartEst.
Aug 1, 2020
Primary completionEst.
Aug 1, 2022
CompletionEst.
Aug 1, 2023
Last update
Oct 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04420130
Lead sponsor
Yanqiao Zhang
Responsible party
Yanqiao Zhang (Director of the hospital, Harbin Medical University) — Sponsor-investigator
First posted
Jun 9, 2020
Start date
Aug 1, 2020 (estimated)
Primary completion
Aug 1, 2022 (estimated)
Completion
Aug 1, 2023 (estimated)
Last update
Oct 4, 2022

Study contacts

Yanqiao Zhang, PhD
principal investigator · Harbin Medical University Cancer Hosptital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Camrelizumab

Start the discussion